Wager, Travis T. published the artcileDiscovery of Two Clinical Histamine H3 Receptor Antagonists: trans-N-Ethyl-3-fluoro-3-[3-fluoro-4-(pyrrolidinylmethyl)phenyl]cyclobutanecarboxamide (PF-03654746) and trans-3-Fluoro-3-[3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl]-N-(2-methylpropyl)cyclobutanecarboxamide (PF-03654764), Related Products of bromides-buliding-blocks, the publication is Journal of Medicinal Chemistry (2011), 54(21), 7602-7620, database is CAplus and MEDLINE.
The discovery of two histamine H3 antagonist clin. candidates is disclosed. The pathway to identification of the two clin. candidates, 6 (PF-03654746, I, R=Et) and 7 (PF-03654764, I, R=isobutyl) required five hypothesis driven design cycles. The key to success in identifying these clin. candidates was the development of a compound design strategy that leveraged medicinal chem. knowledge and traditional assays in conjunction with computational and in vitro safety tools. Overall, clin. compounds 6 and 7 exceeded conservative safety margins and possessed optimal pharmacol. and pharmacokinetic profiles, thus achieving our initial goal of identifying compounds with fully aligned oral drug attributes, “best-in-class” mols.
Journal of Medicinal Chemistry published new progress about 76283-09-5. 76283-09-5 belongs to bromides-buliding-blocks, auxiliary class Fluoride,Bromide,Benzyl bromide,Benzene, name is 4-Bromo-1-(bromomethyl)-2-fluorobenzene, and the molecular formula is C6H8O3, Related Products of bromides-buliding-blocks.
Referemce:
https://en.wikipedia.org/wiki/Bromide,
bromide – Wiktionary